This is the authors' abstract. We don't add key points for this paper.
/L) and confirmed reproducibility (interassay coefficient of variation <10%). Emerging oligoplex and multiplex (fixed-panel) assays conserve on serum and are more cost-effective, but they need regulatory clearance in some countries and are prone to higher rates of detecting asymptomatic sensitization. Ultimately, the patient's clinical history, combined with proof of sensitization, is the final arbiter in the diagnosis of Hymenoptera venom allergy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Blank et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: